Shanghai Zhongshan Hospital

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

264

Clinical Trials↗

All sponsored trials (all statuses)

Pipeline

Pipeline Snapshot

By Phase

13 drugs in development

Approved2

Phase 31

Phase 27

Preclinical6

By Therapeutic Area

top 6

Oncology

947%

Infectious Disease

211%

Nephrology

15%

Hematology

15%

Cardiovascular

15%

Metabolic & Endocrine

15%

R&D Momentum

85/100

Pipeline Velocity

66/100

Trial Completion Rate

93/100

Pipeline Concentration

26/100

Pipeline Freshness

56/100

Strategic Signals

↗Active in Nephrology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Jul 11, 2026

Completed

Impact of Health Lifestyle on Body Weight Post Cessation of Pharmacotherapy in Obese Subjects

Jul 8, 2026

Recruiting

Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents-a Pragmatic Randomized Controlled Trial

Jul 3, 2026

Recruiting

A Study on a Predictive Model for Efficacy and Prognosis of Pancreatic Carcinoma Based on Multimodal Data

Earlier

Jun 30, 2026TrialA Prospective Cohort Study on the Association Between Chronic Psychological Stress and Disease Course Outcomes in Pancreatic Cancer: A Comprehensive Analysis Based on Multidimensional Dynamic Psychological Assessment (MIND-PANC)

Jun 27, 2026TrialA Randomized, Double-blind, Placebo-controlled Study Evaluating the Effect of LAE102 Injection in Combination With Tirzepatide on Body Composition in Obese Participants

Jun 25, 2026TrialEffect of Ertugliflozin on NT-proBNP and Cardiac Function After Acute Myocardial Infarction in Patients With Type 2 Diabetes: A Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(1 drug)

—

Cardiovascular(1 drug)

Hematology(1 drug)

—

Hematology(1 drug)

Immunology(1 drug)

—

Immunology(1 drug)

Infectious Disease(2 drugs)

—

Infectious Disease(2 drugs)

Metabolic & Endocrine(1 drug)

—

Metabolic & Endocrine(1 drug)

Nephrology(1 drug)

—

Nephrology(1 drug)

Oncology(9 drugs)

—

Oncology(9 drugs)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Unknown / Other(2 drugs)

—

Unknown / Other(2 drugs)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)